P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY

P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY

Bibliographic Details
Main Authors:	Rakesh Popat, Sikander Ailawadhi, David Kleinman, Sue Perera, Boris Gorsh, Caitlin Thomas, Sarah Mulnick, Oneill Alicia, Melissa Ross, Maya Hanna, Alexa Molinari, Heather Gelhorn
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970648.98988.1c

Similar Items

Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment
by: Caitlin Thomas, et al.
Published: (2023-11-01)

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
by: Ricardo D. Parrondo, et al.
Published: (2024-04-01)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
by: Ricardo D. Parrondo, et al.
Published: (2022-07-01)

Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
by: Anna Cardellino, et al.
Published: (2023-12-01)

Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma
by: Omar Nadeem, et al.
Published: (2024-02-01)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
by: Jarrod Longcor, et al.
Published: (2022-09-01)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
by: Saurav Das, et al.
Published: (2023-10-01)

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: Shaji Kumar, et al.
Published: (2023-08-01)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
by: Philippe Moreau, et al.
Published: (2023-03-01)

P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
by: M. Hanna, et al.
Published: (2023-05-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

United Kingdom: Citizenship education in the United Kingdom: Comparing England, Northern Ireland, Scotland and Wales
by: Lee Jerome, et al.
Published: (2022-12-01)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
by: O'Reilly, MA, et al.
Published: (2024)

United Kingdom
by: Fisher, S
Published: (2008)

United Kingdom
by: Fisher, S
Published: (2007)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
by: van de Donk NW, et al.
Published: (2012-08-01)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
by: Parva Bhatt, et al.
Published: (2023-02-01)

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: NWCJV Donk, et al.
Published: (2023-10-01)

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
by: A. Nooka, et al.
Published: (2023-05-01)

Flood studies for the United Kingdom Report of the committee on floods in the United Kingdom /
by: Institution of Civil Engineers (Great Britain). Floods Working Party, et al.
Published: (1967)

Mycobacterium bovis Infection, United Kingdom
by: Robert M.M. Smith, et al.
Published: (2004-03-01)

Optimal sequencing in the management of relapsed/refractory myeloma patients
by: Philippe Moreau
Published: (2018-06-01)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
by: Klaus Podar, et al.
Published: (2021-10-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE CURRENT STATE OF PLAY
by: María-Victoria Mateos, et al.
Published: (2015-07-01)

Transport in the United Kingdom /
by: 278804 Maltby, D., et al.
Published: (1982)

Chemfacts: United Kingdom/
Published: (1983)

Mudrocks of the United Kingdom

The End of the United Kingdom
by: Bob Brecher
Published: (2020-01-01)

Immigration Into the United Kingdom
by: Lukáš Nevěděl, et al.
Published: (2015-01-01)

United States defence bases in the United Kingdom
by: Duke, S, et al.
Published: (1985)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
by: Kai Rejeski, et al.
Published: (2023-07-01)

The Contribution of Registered Dietitians in the Management of Hyperemesis Gravidarum in the United Kingdom
by: Kate Maslin, et al.
Published: (2021-06-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Pomalidomide in the management of relapsed/refractory multiple myeloma: A review
by: Sergej Semochkin
Published: (2023-08-01)

Advances and perspective of the immunotherapy for relapsed/refractory multiple myeloma (interview)
by: S. V. Semochkin
Published: (2022-01-01)

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)